Literature DB >> 26378079

Histone Deacetylases in Bone Development and Skeletal Disorders.

Elizabeth W Bradley1, Lomeli R Carpio1, Andre J van Wijnen1, Meghan E McGee-Lawrence1, Jennifer J Westendorf1.   

Abstract

Histone deacetylases (Hdacs) are conserved enzymes that remove acetyl groups from lysine side chains in histones and other proteins. Eleven of the 18 Hdacs encoded by the human and mouse genomes depend on Zn(2+) for enzymatic activity, while the other 7, the sirtuins (Sirts), require NAD2(+). Collectively, Hdacs and Sirts regulate numerous cellular and mitochondrial processes including gene transcription, DNA repair, protein stability, cytoskeletal dynamics, and signaling pathways to affect both development and aging. Of clinical relevance, Hdacs inhibitors are United States Food and Drug Administration-approved cancer therapeutics and are candidate therapies for other common diseases including arthritis, diabetes, epilepsy, heart disease, HIV infection, neurodegeneration, and numerous aging-related disorders. Hdacs and Sirts influence skeletal development, maintenance of mineral density and bone strength by affecting intramembranous and endochondral ossification, as well as bone resorption. With few exceptions, inhibition of Hdac or Sirt activity though either loss-of-function mutations or prolonged chemical inhibition has negative and/or toxic effects on skeletal development and bone mineral density. Specifically, Hdac/Sirt suppression causes abnormalities in physiological development such as craniofacial dimorphisms, short stature, and bone fragility that are associated with several human syndromes or diseases. In contrast, activation of Sirts may protect the skeleton from aging and immobilization-related bone loss. This knowledge may prolong healthspan and prevent adverse events caused by epigenetic therapies that are entering the clinical realm at an unprecedented rate. In this review, we summarize the general properties of Hdacs/Sirts and the research that has revealed their essential functions in bone forming cells (e.g., osteoblasts and chondrocytes) and bone resorbing osteoclasts. Finally, we offer predictions on future research in this area and the utility of this knowledge for orthopedic applications and bone tissue engineering.
Copyright © 2015 the American Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26378079      PMCID: PMC4600951          DOI: 10.1152/physrev.00004.2015

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  218 in total

1.  The chick transcriptional repressor Nkx3.2 acts downstream of Shh to promote BMP-dependent axial chondrogenesis.

Authors:  L C Murtaugh; L Zeng; J H Chyung; A B Lassar
Journal:  Dev Cell       Date:  2001-09       Impact factor: 12.270

Review 2.  Regulatory signal transduction pathways for class IIa histone deacetylases.

Authors:  Maribel Parra; Eric Verdin
Journal:  Curr Opin Pharmacol       Date:  2010-05-04       Impact factor: 5.547

3.  SIK3 is essential for chondrocyte hypertrophy during skeletal development in mice.

Authors:  Satoru Sasagawa; Hiroshi Takemori; Tatsuya Uebi; Daisuke Ikegami; Kunihiko Hiramatsu; Shiro Ikegawa; Hideki Yoshikawa; Noriyuki Tsumaki
Journal:  Development       Date:  2012-02-08       Impact factor: 6.868

4.  Histone H2A.z is essential for cardiac myocyte hypertrophy but opposed by silent information regulator 2alpha.

Authors:  Ieng-Yi Chen; Jacqueline Lypowy; Jayashree Pain; Danish Sayed; Stan Grinberg; Ralph R Alcendor; Junichi Sadoshima; Maha Abdellatif
Journal:  J Biol Chem       Date:  2006-05-10       Impact factor: 5.157

5.  Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3.

Authors:  Jong Seok Kang; Tamara Alliston; Rachel Delston; Rik Derynck
Journal:  EMBO J       Date:  2005-06-30       Impact factor: 11.598

Review 6.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

7.  Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1.

Authors:  Masaya Tanno; Jun Sakamoto; Tetsuji Miura; Kazuaki Shimamoto; Yoshiyuki Horio
Journal:  J Biol Chem       Date:  2006-12-30       Impact factor: 5.157

8.  The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.

Authors:  Jitesh Pratap; Jacqueline Akech; John J Wixted; Gabriela Szabo; Sadiq Hussain; Meghan E McGee-Lawrence; Xiaodong Li; Krystin Bedard; Robinder J Dhillon; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jennifer J Westendorf; Jane B Lian
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

9.  Exome sequencing identifies a de novo mutation in HDAC8 associated with Cornelia de Lange syndrome.

Authors:  Lei Feng; Daizhan Zhou; Zhou Zhang; Yun Liu; Yabo Yang
Journal:  J Hum Genet       Date:  2014-08-07       Impact factor: 3.172

10.  Fortifying the link between SIRT1, resveratrol, and mitochondrial function.

Authors:  John M Denu
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

View more
  58 in total

1.  Parathyroid hormone-induced down-regulation of miR-532-5p for matrix metalloproteinase-13 expression in rat osteoblasts.

Authors:  Vishal Mohanakrishnan; Arumugam Balasubramanian; Gokulnath Mahalingam; Nicola Chennell Partridge; Ilangovan Ramachandran; Nagarajan Selvamurugan
Journal:  J Cell Biochem       Date:  2018-04-06       Impact factor: 4.429

Review 2.  Dynamic regulation of lysine acetylation: the balance between acetyltransferase and deacetylase activities.

Authors:  Kelly A Hyndman; Mark A Knepper
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-12

Review 3.  Stem cell-derived exosomes: A promising strategy for fracture healing.

Authors:  Zi-Chen Hao; Jun Lu; Shan-Zheng Wang; Hao Wu; Yun-Tong Zhang; Shuo-Gui Xu
Journal:  Cell Prolif       Date:  2017-07-25       Impact factor: 6.831

4.  Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.

Authors:  Héctor F Araya; Hugo Sepulveda; Carlos O Lizama; Oscar A Vega; Sofia Jerez; Pedro F Briceño; Roman Thaler; Scott M Riester; Marcelo Antonelli; Flavio Salazar-Onfray; Juan Pablo Rodríguez; Ricardo D Moreno; Martin Montecino; Martine Charbonneau; Claire M Dubois; Gary S Stein; Andre J van Wijnen; Mario A Galindo
Journal:  J Cell Biochem       Date:  2018-06-19       Impact factor: 4.429

5.  Chromatin dynamics regulate mesenchymal stem cell lineage specification and differentiation to osteogenesis.

Authors:  Hai Wu; Jonathan A R Gordon; Troy W Whitfield; Phillip W L Tai; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-08       Impact factor: 4.490

Review 6.  Histone Deacetylases in Cartilage Homeostasis and Osteoarthritis.

Authors:  Lomeli R Carpio; Jennifer J Westendorf
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

Review 7.  Epigenetics as a New Frontier in Orthopedic Regenerative Medicine and Oncology.

Authors:  Andre J van Wijnen; Jennifer J Westendorf
Journal:  J Orthop Res       Date:  2019-04-25       Impact factor: 3.494

Review 8.  Epigenetics in osteoarthritis: Potential of HDAC inhibitors as therapeutics.

Authors:  Nazir M Khan; Tariq M Haqqi
Journal:  Pharmacol Res       Date:  2017-08-18       Impact factor: 7.658

9.  Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.

Authors:  Lomeli R Carpio; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  Connect Tissue Res       Date:  2016-09-23       Impact factor: 3.417

Review 10.  The Spectrum of Fundamental Basic Science Discoveries Contributing to Organismal Aging.

Authors:  Joshua N Farr; Maria Almeida
Journal:  J Bone Miner Res       Date:  2018-08-13       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.